Myelofibrosis
ICD-10 D75.81 is a billable code used to indicate a diagnosis of myelofibrosis.
Myelofibrosis is a type of chronic myeloproliferative neoplasm characterized by the replacement of bone marrow with fibrous tissue, leading to ineffective hematopoiesis. This condition often results in splenomegaly (enlarged spleen) and can cause various hematological abnormalities, including anemia, leukopenia, and thrombocytopenia. Patients may present with symptoms such as fatigue, weakness, night sweats, and bone pain. The pathophysiology involves mutations in genes such as JAK2, CALR, and MPL, which contribute to abnormal cell proliferation and fibrosis in the bone marrow. Myelofibrosis can lead to complications such as acute leukemia and portal hypertension due to splenic congestion. Diagnosis typically involves blood tests, bone marrow biopsy, and imaging studies to assess spleen size and function. Management may include supportive care, blood transfusions, and targeted therapies aimed at the underlying genetic mutations.
Detailed blood work results, bone marrow biopsy findings, and treatment plans.
Patients presenting with anemia, splenomegaly, or leukopenia requiring evaluation.
Ensure clear documentation of genetic testing results and treatment responses.
Oncological assessments, treatment protocols, and follow-up care documentation.
Management of patients undergoing chemotherapy or targeted therapy for myelofibrosis.
Document any complications or secondary malignancies that may arise.
Used to monitor blood counts in patients with myelofibrosis.
Document the reason for the CBC and any abnormal findings.
Hematology specialists should ensure comprehensive reporting of all blood parameters.
Common symptoms include fatigue, weakness, splenomegaly, night sweats, and bone pain. Patients may also experience anemia and other blood-related issues.
